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ABSTRACT: 
 
Bleeding related wound complications cause significant morbidity in 
lower limb arthroplasty surgery.  Patients who require therapeutic 
anticoagulation in the peri operative period are potentially at higher 
risk of these complications.  This is a retrospective case control study 
reviewing all primary total hip replacements performed in a single 
center over a five year period and comparing outcomes of the patients 
on warfarin with a double-matched control group of patients not on 
warfarin.  
The warfarin group had significantly higher risk of deep joint infection 
(9% vs 2.2%), haematoma/ wound ooze (28% vs 4%) and superficial 
infection (13.5% vs 2.2%).  
 
Managing the total hip arthroplasty patient with therapeutic 
anticoagulation is a balance between the risk of thromboembolic 
disease and bleeding related complications. Improved understanding 
of this risk will better allow the patient to make an informed decision 
regarding their elective arthroplasty surgery.  
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INTRODUCTION: 
 
Bleeding related wound complications, including deep infection, 
superficial infection and haematoma cause significant morbidity in 
lower limb joint arthroplasty surgery.  It has long been observed that 
patients requiring therapeutic anti-coagulation within the peri-
operative period have higher rates of bleeding related complications 
and those requiring intravenous heparin additionally appear to do 
poorly (1,2,3,4). 
 
Bleeding complications related to anticoagulation with both warfarin 
and heparin are well described in both the non-surgical and surgical 
patient.  Jeurgens, Semsarian et al in 1997 (5) in the American 
Journal of Cardiology reported a 5.5% risk of bleeding complications 
in patients treated with intravenous heparin.  Audebert, Schnek et al 
in 2008 (6) compared treatment of the non-surgical patient with acute 
stroke and TIA with bridging intravenous heparin versus other 
conventional measures (anti-platelet agents, low molecular weight 
heparin) and did not find a significant difference in major 
complications, but did report that the bridging heparin group had a 
longer hospital stay.  
 
In 2003, Dunn and Turpie (7), in a systemic review of the 
Perioperative Management of patients receiving anticoagulants 
concluded that more studies were required to better assess the 
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patient’s risk of thromboembolic and bleeding complications. Sachs , 
Smith  et al 2003 (2) produced a large study comparing complications 
of anticoagulation for the prevention of thromboembolic disease in the 
knee arthroplasty patient and found that the warfarin group had twice 
the infection rate as the control group (0.6% vs 0.3%). They excluded 
patients who had previously been on warfarin for chronic atrial 
fibrillation or thromboembolic events and thus no patients required 
bridging with heparin. Few studies have been published that 
specifically look at complications in the arthroplasty patient 
therapeutically treated with oral warfarin plus or minus intravenous 
heparin. 
 
Our aging society and the associated burden of increased degenerative 
disease may also have important implications in bleeding related 
complications in orthopaedic surgery.  Eikelboom, Ginsberg et al 
(1999) (3) published a systematic review investigating  interventions 
and  outcomes in the prevention of thromboembolic events in older 
orthopaedic patients and described an increase in venous 
thromboembolism (VTE) risk as well as an increased risk of bleeding 
complications related to the management of these VTE events.   A 
systematic review in 1999 by Hutten, Lensing et al (8) reported an up 
to two fold increase in bleeding complications in elderly people on 
anticoagulants. Campbell, Hull et al in 1996 (9) looked specifically at 
heparin use in the elderly and identified increasing age as an 
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independent risk factor for bleeding complications in patients on 
intravenous heparin. 
 
The aim of this study is to investigate the relationship between post-
operative bleeding and wound complications in the patient requiring 
therapeutic warfarin, plus or minus heparin, in total hip arthroplasty 
surgery. 
 
MATERIALS AND METHODS: 
 
This is a retrospective case control study granted ethics approval by 
the Human Research Ethics Committee at The Prince Charles 
Hospital. 
 
Data collected by the hospital Orthopaedic Research and Audit Unit 
identified all Primary Total Hip Arthroplasty operations performed in 
the period 2004 – 2008, at the Prince Charles Hospital.   The 
pathology results of these patients were reviewed and any patient with 
an abnormal coagulation profile was identified for medical record 
(chart) review.  After reviewing the patient’s medical records, a study 
group was formed, defined as any patient requiring therapeutic 
warfarin plus or minus heparin within the 30 day peri-operative 
period, following their total hip replacement. 
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The data collected that was  specific to the study group included 
indications for warfarinisation , the protocol used for post operative 
warfarin, whether the patient required a bolus of IV heparin, INR 
levels and APTT levels. 
 
A control group was formed by using the same arthroplasty database 
and matching the study group two to one, for gender and age. It was 
also noted whether each patient was diabetic. 
 
The major outcome measures for both the study and control group 
were recorded and included: 
 
1. Deep infection  -  defined as microbiological evidence of infection 
on operative tissue samples or joint aspirate 
2. Excessive wound ooze or haematoma  -  documented by a doctor 
in the ward notes 
 
The secondary outcome measures were: 
 
1. Superficial Infection  -  defined as  positive superficial wound 
swabs confirming infection in laboratory studies, or patients 
commenced on antibiotics for presumed superficial infection 
2. Return to theatre for washout in the period of their initial post-
operative hospital stay, prior to discharge 
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3. Revision for any cause from the time of arthroplasty surgery to 
the time of data collection 
 
These outcome measures were compared for the study group and the 
control group and then further sub-analysed by comparing those in 
the study group who required IV heparin to the rest of the study 
group. 
 
A medical statistician analysed the results utilising the t-test,  Chi-
squared test and the Fishers exact test as appropriate for the data 
type. Adjusting for multiple testing by using the Bonferonni 
calculation, significance for the major outcomes was set at 2.5%, and 
for the secondary outcomes was 1.7%. 
 
 
RESULTS: 
 
In the five year period between 2004 – 2008, 1047  primary total hip 
arthroplasty operations were performed under the care of seven 
different consultants. 
 
There were 89 patients in the study group, 47 male and 42 female  
and 179 patients in the control group. These two groups were 
statistically matched for gender and age (Table 1). The most common 
indication for arthroplasty surgery was osteoarthritis in both groups  
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(93% vs 95%)  There was no significant difference in the number of 
diabetic patients in each group (6% vs 6.7%). Standard chemical 
thromboprophylaxis in the control group was aspirin 300mg, one dose 
daily for six weeks. One surgeon used subcutaneous heparin three 
times per day for forty-eight hours post operatively prior to using 
aspirin for the remainder of the six weeks. 
 
The most common indication for warfarinisation was previous venous 
thromboembolis (VTE) 34/89 (38%), followed by atrial fibrillation 
33/80 (37%). Mechanical valves, post-operative VTE, cardiac stents 
and procoagulant disorders made up the remainder of the indications. 
(Figure 1).  New, post-operative VTE,( within 30 post-operative days) 
occurred in 11/ 1047 (1%) of the entire  total hip arthroplasty group 
in the five year period. 
 
 
Warfarin protocol was varied (Table 2).  Intravenous heparin was used 
in high risk patients whose indication required that they be bridged 
with heparin until their warfarin became therapeutic. This made up 
27/89 (30%) of the study group. Warfarin levels were measured by 
International Normalised Ratio (INR) and exceeded therapeutic levels 
(>2 - 3.5) 11% of the time. Heparin was monitored by Activated Partial 
Thromboplastin Time (APTT) and remained in the therapeutic range ( 
60-90) 81% of the time. 
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Comparison of both of the major outcome measures were significant 
(Table 3/ Figure 2). The deep infection rate of the study group was 9% 
compared to the control group 2.2% (p  0.023) and excessive wound 
ooze/ haematoma was 28% and 4% ( p < 0.001).  In the secondary 
outcomes, superficial infection rate was significant 13.5% and 2.2% (p 
< 0.001).   
 
Patients requiring intravenous heparin were further sub analysed as 
compared to the rest of the study group. (Table 3)  The significant 
result was excessive wound ooze/ haematoma (44% vs 4%  p  0.023).   
In both groups, 19/32  (60%) patients who had excessive wound ooze/ 
haematoma required a transfusion.  Other outcomes were not found 
to be significant when adjusted for multiple testing. 
 
 
DISCUSSION: 
 
The requirement of therapeutic anti-coagulation in the peri-operative 
period is a tenuous balance between the complications of thrombo-
embolic disease and bleeding-related morbidity.   Deep and superficial 
wound infection and wound complications including excessive ooze 
and haematoma can be catastrophic in the arthroplasty patient (1). 
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This is the largest study in the current literature specifically looking at 
bleeding complications related to anticoagulation in hip arthroplasty 
surgery. This was possible because of access to a population of 
patients with multiple indications for warfarinisation.  Other strengths 
included full access to medical records for all patients in the study 
and no patients lost to follow-up.  
 
Limitations to our study include matching for only gender and age and 
not other medical co-morbidities. Diabetes is known to increase the 
risk of complications in total hip arthroplasty (10) and the percentage 
of diabetics between our study and control group was essentially the 
same ( 6% vs 6.7%) and not significant. It is reasonable, however to 
suggest that patients with multiple medical co-morbidities are 
perhaps more likely to require anticoagulation and could have hidden 
biases toward deep infection and wound complications that were not 
identified by a purely gender and age match.  Larger numbers would 
also have helped us more clearly define the risks particularly related 
to the use of intravenous heparin. 
 
The monitoring of anticoagulants is dependent on the agent, but well 
established markers exist for warfarin (INR) and heparin (APTT). There 
are, however difficulties keeping serum levels in the therapeutic range. 
A systematic review by Krishnaswany, Lincoff et al 2010 (11) on the 
use and limitations of unfractionated heparin found only a minority of 
patients in the appropriate therapeutic heparin range and reported an 
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increase in both bleeding and ischaemic related complications due to 
either under or over anticoagulation.  Mika, Behounek et al 2004 (4) 
reported a 20% risk of bleeding complications in patients on warfarin 
for DVT prophylaxis in orthopaedic arthroplasty surgery and identified 
> 8% of patients exceeding the therapeutic range. Jeurgen et al (1997) 
(5) identified no link between heparin dose or duration of treatment to 
haemorrhagic complications.  In our study, warfarin levels exceeded 
therapeutic range 11% of the time, and heparin levels exceeded 
therapeutic range 19% of the time. 
 
 
The results of our study have highlighted significant increase in risk of 
deep infection, wound haematoma/ ooze and superficial infection in 
the total hip arthroplasty patient requiring warfarin in the peri 
operative period. This risk is even higher in patients requiring 
intravenous heparin. By correlating this risk with the broad 
indications for warfarinisation identified in our study, the challenge is 
to determine whether therapeutic anticoagulation can be either 
completely  avoided, or not bridged with heparin in any of these 
patient groups. If this is not possible, then the clinician should be 
better able to quantify the risk of complications to patients thus 
allowing them to make a more informed decision prior to  elective hip 
arthroplasty surgery.  
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The largest group requiring warfarinisation was previous  venous 
thromboembolis (VTE) ( 38%).  Orthopaedic guidelines recommend 
that patients in this group require warfarinisation post-operatively. 
(12) 
 
Patients on warfarin for atrial fibrillation (AF) also made up a large 
portion of our study group (37%).   A plethora of literature exists 
investigating the risk of embolic stroke in patients with AF not treated 
with warfarin. Multiple risk stratification measures for patients with 
AF are used by physicians to determine the requirement of warfarin 
(13).  Review of each patient’s individual risk factors, in consultation 
with the physicians, may prevent unnecessary warfarinisation in the 
lower risk AF patient.   In 2008, Garcia D and Regan S et al (14) 
concluded that patients off anticoagulation for brief <5 day periods for 
minor or outpatient procedures were at low risk of thromboembolic 
events.  The 2006 American College of Cardiology Guidelines (15) and  
the recent  Peri operative Management of Chronic Anticoagulation 
AAOS Guidelines by Thakur N, Czerwein J et al 2010 (12), make 
recommendations for anticoagulation according to various risk 
stratification measures.  
 
Post-operative VTE encompassed 12.4% of our indications for 
warfarinisation.  The key to decreasing the number of patients 
requiring anticoagulation for post op VTE continues to be prevention, 
a topic of enormous importance and literature interest, but not 
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directly addressed here.  The risk of a symptomatic thromboembolic 
event in the total hip arthroplasty patient is quoted between 0.6% - 
4% (16,17,18,19), slightly higher than the number of of new VTE 
episodes in our data (11/1047  1%).    
 
The higher risk group includes mechanical valves and procoagulant 
disorders.  The risk of thrombotic complications for these patients off 
anti-coagulation can be catastrophic and it has been recommended  
that the high risk patient be bridged with intravenous heparin while 
their warfarin becomes therapeutic (20).  It is in this group that 
counselling the patient regarding their potential increased risk of 
infective complications is of great importance. Knowledge and 
understanding of this risk, may assist the high risk patient make an 
informed decision regarding elective hip arthroplasty surgery. The use 
of inferior vena cava filters in similarly high risk spinal patients has 
been used to good effect (21) and may be an option for arthroplasty 
patients. 
 
In the past, perhaps the full burden of bleeding related complications 
has not been appreciated. Now, with more studies identifying high risk 
of bleeding complications in the arthroplasty group managed with 
therapeutic anticoagulation ( Simpson, Brew et al 2010) (22), a better 
balance can be achieved particularly in the lower risk patient.  
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CONCLUSION: 
 
Bleeding related morbidity in total hip arthroplasty patients requiring 
therapeutic anticoagulation is significant. Patients requiring warfarin 
during the peri operative period have increased risk of deep infection, 
superficial infection and other wound associated complications.  
 
A multi-specialty team based approach needs to be adopted to better 
stratify each patient’s risk and determine the absolute individual 
requirement for anticoagulation to help prevent serious complications, 
and better counsel  patients prior to elective total hip arthroplasty 
surgery. 
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TABLES & FIGURES: 
 
Table 1: Patient demographics 
 
  Number Mean age (SD; range) Range 
Gender 
(M:F) 
Diabetic 
(%) 
Study group 89 71.1 (9.7; 39-88) 39-88 47:42 11/89 (6%) 
Control 
group 179 70.7 (9.5; 39-88) 39-88 94:85   
p-value   p=0.779   p=0.964 p=0.684 
 
 
 
Table 2: Warfarin protocols used 
PROTOCOL   % of patients/89 
1 SC Heparin 5000u BD with warfarin started 
within 24 hrs of surgery 
3.50 
2 SC Heparin 5000u TDS or QID with warfarin 
started within 24 hrs of surgery 
22.50 
3 IV Heparin peri-operatively 30.30 
4 Aspirin 150mg or 300mg + warfarin started 
within 24 hrs of surgery 
13.50 
5 Low molecular weight heparin LMWH treatment 
dose + warfarin started within 24hrs of surgery 
3.30 
6 Low molecular weight heparin LMWH low dose 
+ warfarin started within 24rs of surgery 
5.60 
7 Warfarin alone 21.30 
SC, subcutaneously; bd, twice a day; tds, 3 times a day; qid, 4 times a daily 
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Table 3: Post-operative complications 
 
     
Outcome 
Study 
(89) 
Control 
(179) p-value 
IV Heparin 
(27) 
P value vs 
rest of study 
group 
Major outcomes 
     Deep Infection 8 4 p=0.023* (F) 3 p= 0.69 (F) 
Excessive Wound 
Ooze/ Haematoma 25 7 p<0.001* (χ²) 12 p=0.023* (χ²) 
Secondary outcomes 
     Superficial Infection 12 4 p=0.001* (χ²) 4 p=1.0 (F) 
Return to OT for 
Washout 3 2 p=0.34 (F) 2 p=0.22 (F) 
Revision any cause 5 4 p=0.16 (F) 2 p=0.64 (F) 
  
( 
 
       F, Fishers exact test; (χ²) Chi squared test 
* Statistically significant 
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Figure 1: Indications for warfarinisation 
 
 
 
Figure 2: Complications for study, IV heparin and control groups 
 
